By

CR2O

LARISSA consortium reaches milestone: Novel Rift Valley fever vaccine dosed in Phase I human trial

The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA[1] consortium and which started this week, will assess...
Read More

First clinical trial authorisation under ECTR is a fact

The clinical trial application of the LARISSA study is the first application submitted successfully by CR2O under the new European Clinical Trial Regulation (ECTR). The ECTR is the new regulation...
Read More

Freya Pharma Solutions to start pivotal Phase III study with CR2O as clinical operational partner

Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD). Freya Pharma...
Read More

Citryll to start first-in-human studies with CR2O as clinical operations partner

Citryll has planned the start of first in human studies for its development candidate CIT-013 for July 2021. CR2O is proud to be a part of Citryll’s exiting journey offering...
Read More

CR2O to manage First-in-Human trial with Dyadic’s SARS-CoV-2-S-RBD vaccine candidate DYAI-100

CR2O is proud to announce today it will manage and further support the clinical and preclinical development of DYAI-100, Dyadic’s C1 produced SARS-CoV-2-S-RBD vaccine candidate. The first-in-human trial with DYAI-100...
Read More

CR2O profiled in Biotech NEWS and Life Sciences

Dutch industry magazine Biotech NEWS and Life Sciences has profiled CR2O in their 2020 Winter edition. Biotech NEWS and Life Sciences is a national magazine reporting on trends and news within health...
Read More

H2020 awards contract to ENDFLU, CR2O coordinated vaccine trial

The EU Research and Innovation programme HORIZON 2020 has awarded a contract to a consortium that aims towards a next generation influenza vaccine to protect citizens worldwide (an EU-India collaboration)....
Read More

GLORIA aims to prove chronic low dose glucocorticoids are highly effective and safe in elderly patients

The EU Research and Innovation programme HORIZON 2020 has awarded contract worth up to 6 million euro’s to consortium led by Amsterdam Medical Center under grant agreement No 634886. GLORIA...
Read More

H2020 awards contract to develop a monoclonal antibody against COVID-19

The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 3 million euro’s to a European consortium led by ErasmusMC in collaboration with Harbour Antibodies...
Read More

Update COVID-19: Safeguarding health and safety

As a result of the COVID-19 pandemic, CR2O has adapted its contingency plan aimed to guarantee the safety and well-being of patients, employees, clients and continuity of our services.By following...
Read More
1 2